Patents Assigned to Ortho Pharmaceutical Corporation
  • Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigens, antibody, and methods
    Patent number: 4624925
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: November 25, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • 4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents
    Patent number: 4617392
    Abstract: 4-Alkyl-5,6-, 6,7-methylenedioxy-2-1[H]-quinazolinones are prepared from 2,3-methylenedioxyacetophenones. The 4-alkyl-5,6-, 6,7-methylenedioxy-2-1[H]-quinazolinones are active as cardiotonic agents.
    Type: Grant
    Filed: September 29, 1983
    Date of Patent: October 14, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Victor T. Bandurco, Stanley C. Bell, Donald W. Combs, Robert Falotico
  • Alkyl 2-carboalkoxy-3,4-dialkoxybenzenecarbamates and process for their preparation
    Patent number: 4617417
    Abstract: A process for the preparation of alkyl 2-carboxy-3,4-dialkoxybenzenecarbamates is described. The carbamates are useful intermediates in the preparation of 8-halo-5,6-dialkoxyquinazoline-2,4-diones. The diones are useful as cardiotonic agents.
    Type: Grant
    Filed: July 29, 1985
    Date of Patent: October 14, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Richard A. Conley, Donald L. Barton
  • Triphasic oral contraceptive
    Patent number: 4616006
    Abstract: A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen.
    Type: Grant
    Filed: June 13, 1985
    Date of Patent: October 7, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Samuel A. Pasquale
  • Hybrid cell line for producing monoclonal antibody to a human T cell antigen, antibody, and methods
    Patent number: 4614720
    Abstract: Hybrid cell line for production of monocloral antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: September 30, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Total synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabi cyclo[3.2.1]octane-1-acetic acid
    Patent number: 4603213
    Abstract: The synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicy clo[3.2.1]octane-1-acetic acid from its terminal double bond isomer is described. The acetic acid compound is a contragestional agent.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: July 29, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Zoltan G. Hajos
  • Substituted 2-amino-4(1H)pyridones, 7-pyrrolo[1,2-a]pyridinones, 2-quinolizinones, 7-thiazolo[3,2-a]pyridinones and 2-pyrido[1,2-a]azepinones as vasodilators and bronchodilators
    Patent number: 4602013
    Abstract: Substituted 2-amino-4(1H)pyridones are provided which are renal vasodilators and bronchodilators.
    Type: Grant
    Filed: February 8, 1984
    Date of Patent: July 22, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Jack B. Jiang
  • Substituted dioxopyridopyrimidines
    Patent number: 4596805
    Abstract: Substituted dioxopyridopyrimidines are provided which are useful as calcium antagonists and anti-hypertensive agents.
    Type: Grant
    Filed: June 13, 1984
    Date of Patent: June 24, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Jack B. Jiang
  • Bursopoietin
    Patent number: 4584284
    Abstract: A synthetic peptide which possesses the ability to specifically induce the differentiation of precursor B cells into mature B-cells capable of producing antibody.
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: April 22, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Tapan Audhya, Daniel J. Kroon, George Heavner, Gideon Goldstein
  • Prophylactic device and method
    Patent number: 4576156
    Abstract: A prophylactic or contraceptive device made from a thermoplastic polyurethane material having a generally cylindrical configuration with a closed end.
    Type: Grant
    Filed: April 17, 1978
    Date of Patent: March 18, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Manfred F. Dyck, Walter A. Haine
  • 3,4-Dialkoxy-2-alkylcarbonyl analino compounds
    Patent number: 4556739
    Abstract: A process for preparing 4-alkyl-2(1H)quinazolinone-1-alkanoic acid derivatives is described. The 4-alkyl-2(1H)quinazolinones are useful as cardiovascular agents.
    Type: Grant
    Filed: July 2, 1984
    Date of Patent: December 3, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Ramesh M. Kanojia, Victor T. Bandurco, Seymour D. Levine, Dennis M. Mulvey, Alfonso J. Tobia
  • Substituted 4-alkyl-2-(1H) quinazolinone-1-alkanoic acid derivatives
    Patent number: 4555570
    Abstract: A process for preparing 4-alkyl-2-(1H) quinazolinone-1-alkanoic acid derivatives is described. The 4-alkyl-2-(1H) quinazolinones are useful as cardiovascular agents.
    Type: Grant
    Filed: September 29, 1983
    Date of Patent: November 26, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Ramesh M. Kanojia, Victor T. Bandurco, Seymour D. Levine, Dennis M. Mulvey, Alfonso J. Tobia
  • Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters
    Patent number: 4555571
    Abstract: The synthesis of substituted 2(1H)-quinazolinone-1-alkanoic acids and their esters is described. The novel quinazolinones are renal vasodilators and as such reduce vascular resistance to renal blood flow. The quinazolinones are useful as cardiovascular agents.
    Type: Grant
    Filed: September 29, 1983
    Date of Patent: November 26, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Victor T. Bandurco, Seymour D. Levine, Dennis M. Mulvey, Alfonso J. Tobia
  • Conformationally restricted thymopentin-like compounds
    Patent number: 4547489
    Abstract: Immunoregulating peptides are disclosed which are cyclic peptides similar to thymopentin. These peptides are useful for their effects on the immune system, especially the treatment of thymic deficiencies.
    Type: Grant
    Filed: June 11, 1984
    Date of Patent: October 15, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Gideon Goldstein, George Heavner, Tapan Audhya, Foe-Siong Tjoeng
  • Triphasic oral contraceptive
    Patent number: 4544554
    Abstract: A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen.
    Type: Grant
    Filed: May 4, 1984
    Date of Patent: October 1, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Samuel A. Pasquale
  • Triphasic oral contraceptive
    Patent number: 4530839
    Abstract: A method of contraception in which an estrogen and a progestogen are administered daily for 21 days, the first seven days at a low contraceptively effective daily dose, the next 7 days at a daily progestogen dose about 1.5-2 times that of the first 7 days, and the next 7 days at a daily progestogen dose of 2-2.5 times that of the first 7 days, provided that the dosage of the estrogen is maintained at a constant level for the entire 21 days.
    Type: Grant
    Filed: September 26, 1983
    Date of Patent: July 23, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Samuel A. Pasquale
  • Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
    Patent number: 4515893
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells and cutaneous T lymphoma cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: May 7, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Hybrid cell line for producing monoclonal antibody to human helper T cells
    Patent number: 4515895
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human helper T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: May 7, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Hybrid cell line for producing monoclonal antibody to human T cells
    Patent number: 4515894
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: May 7, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Vaginal applicator
    Patent number: D279504
    Type: Grant
    Filed: May 15, 1981
    Date of Patent: July 2, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Dirk Tump